The effect of hydroxcarbamide therapy on survival of children with sickle cell disease

Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease

(2013) Sophie Lanzkron et al.   ANNALS OF INTERNAL MEDICINE

Impact of hydroxyurea on clinical events in the BABY HUG trial

(2012) C. D. Thornburg et al.   BLOOD

Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients

(2012) Valentine Brousse et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin

(2011) J. D. Lebensburger et al.   BLOOD

Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

(2011) Patrick T. McGann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

(2011) Winfred C Wang et al.   LANCET

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial

(2011) Patrick T. McGann et al.   PEDIATRIC BLOOD & CANCER

Mortality in Sickle Cell Anemia in Africa: A Prospective Cohort Study in Tanzania

(2011) Julie Makani et al.   PLoS One

Population Estimates of Sickle Cell Disease in the U.S.

(2010) Kathryn L. Hassell   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients

(2010) Akito Nozaki et al.   ANTIVIRAL THERAPY

Improved survival of children and adolescents with sickle cell disease

(2010) C. T. Quinn et al.   BLOOD

Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis

(2010) Meenakshi Ramakrishnan et al.   LANCET INFECTIOUS DISEASES

Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening

(2009) R. Hardie et al.   ANNALS OF TROPICAL PAEDIATRICS

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

(2009) E. Voskaridou et al.   BLOOD

Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case–control study

(2009) Thomas N Williams et al.   LANCET

Global epidemiology of haemoglobin disorders and derived service indicators

(2008) Bernadette Modell   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea

(2008) Sharbel Maluf et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital

(2008) Jean L. Raphael et al.   PEDIATRIC BLOOD & CANCER

Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain

(2008) Lisa K. Morrissey et al.   PEDIATRIC BLOOD & CANCER

Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life

(2008) T. V. Adamkiewicz et al.   PEDIATRICS

Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium

(2007) Johnson Haynes et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY